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Abstract
Infants in the neonatal intensive care unit are highly 
susceptible to healthcare associated infections (HAI), 
with a substantial impact on mortality, morbidity and 
healthcare costs. Effective skin disinfection with topical 
antiseptic agents is an important intervention in the 
prevention or reduction of HAI. A wide array of antiseptic 
preparations in varying concentrations and combinations 
has been used in neonatal units worldwide. In this article 
we have reviewed the current evidence of a preferred 
antiseptic of choice over other agents for topical skin 
disinfection in neonates. Chlorhexidine (CHG) appears 
to be a promising antiseptic agent; however there exists 
a significant concern regarding the safety of all agents 
used including CHG especially in preterm and very low 
birth weight infants. There is substantial evidence to 
support the use of CHG for umbilical cord cleansing and 
some evidence to support the use of topical emollients 
in reducing the mortality in infants born in developing 
countries. Well-designed large multicentre randomized 
clinical trials are urgently needed to guide us on the 
most appropriate and safe antiseptic to use in neonates 
undergoing intensive care, especially preterm infants.
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Core tip: Topical antiseptic agents play a crucial role 
in the prevention of nosocomial infections in infants 
admitted to neonatal intensive care unit. There is a 
paucity of good quality studies to guide us on the most 
effective and safe antiseptic preparation, concentration 
and combination for use in neonatal skin disinfection. 
Further research is urgently needed to identify the 
most appropriate and safe antiseptic use in neonates 
including preterm and very low birth weight infants.
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INTRODUCTION
Sepsis is one of the leading causes of death in infants 
admitted to the neonatal unit[1-5]. Neonatal sepsis is 
also associated with significant morbidity including 
prolonged hospital stay and increases in health care 
costs[6,7]. Studies have shown that sepsis in preterm and 
very low birth weight infants (VLBW) infants could lead 
to significant neurodevelopmental morbidity secondary 
to associated white matter injury[8-10]. Healthcare 
associated infections (HAI) account for vast majority 
of neonatal sepsis, with Catheter Related Bloodstream 
Infection (CRBSI) being the most common nosocomial 
infection[11,12]. The neonatal units, to reduce or prevent 
the HAI/CRBSI have adopted several strategies and 
use of an effective topical antiseptic agent is one of 
the integral components[11,13,14]. Centers for Disease 
Control and Prevention (CDC)[15] has made a specific 
recommendation for skin preparation before cannulation 
and central venous catheter insertion for adults and 
children 2 mo or older. Similarly United Kingdom 
national evidence based guidelines[16] recommend the 
use of 2% chlorhexidine gluconate (CHG) in 70% 
Isopropyl alcohol for skin antisepsis prior to venous 
cannulation and Central Venous Catheter (CVC) 
insertion in the same age group. However there is 
no specific guidance recommendation on antiseptic 
of choice for infants less than 2 mo. Wide range of 
antiseptics has been used in neonatal units all over 
the world, but good evidence is lacking, and the most 
appropriate and safe antiseptic solution to use on the 
skin remains controversial. The purpose of this review 
is to comprehensively examine the available literature 
on use of topical antiseptics in neonates and to identify 
evidence based recommendations for clinical practice. In 
this review we did not include the evidence of antiseptic 
use for hand hygiene in neonatal units.
BACKGROUND
HAI is a major problem in neonates that incur sig-
nificant health and economic burden to the society. 
Gray et al[17] reported that nosocomial infections 
related to coagulase negative staphylococcus pro-
longed the hospital stay by 14.0 ± 4.0 d (P < 0.01) 
and an associated increase in hospital charges of 
$25090 ± 12051 (P < 0.05). In another report 
nosocomial infections were found to increase costs by 
26% in < 750 g and 80% in 1250-1500 g infants and 
the length of stay was increased by 4-7 d in VLBW 
infants[18].
Preterm neonates are prone for infection because 
they have functionally immature immune system with 
extremely low immunoglobulin levels, complement 
activity, and neutrophil storage pool and function[19]. 
In addition, preterm infants lack an effective skin 
barrier. Stratum Corneum, which is responsible for 
providing an effective epidermal barrier, is not well 
developed until 32-34 wk of gestation. For babies 
born < 34 wk, it takes about 4-5 wk for the skin 
to mature which makes them more vulnerable to 
infections during this period[20-22]. Other risk factors 
for hospital-acquired infections include the presence 
of intravascular catheters, other invasive devices, 
mechanical ventilation, parenteral nutrition and use of 
broad-spectrum antibiotics[23].
CRBSI is the most common HAI[12] and is estimated 
to cause up to 70% of all hospital acquired infections in 
preterm infants[11]. Catheter hub colonisations followed 
by exit site were the strongest predictors of CRBSI in 
NICU[24]. Multi-faceted interventional strategies in the 
form of care bundles have been developed in neonates 
worldwide to reduce the HAI. There are several reports 
from all over the world, that catheter care bundles can 
reduce the risk of nosocomial and CRBSI[11,13,25]. One of 
the key steps included within the care bundles is that 
skin is appropriately disinfected to prevent the entry 
of microorganisms as well as to reduce the risk of 
subsequent infection. It is widely accepted; from adult 
and paediatric studies that CHG is most effective for 
skin antisepsis[26] and is recommended as best practice 
in various guidelines[15,16].
Antiseptics used in neonatal units
An ideal antiseptic agent should be effective against 
a wide range of microorganisms, have an immediate 
onset of action, have residual and long term effect, 
not be inactivated by the presence of organic material 
e.g., blood, have minimum toxic effects on the skin 
and the organ systems[27,28]. A variety of topical 
antiseptics have been used in varying concentrations 
and combinations. Surveys from United States, United 
Kingdom, Australia and New Zealand showed that 
CHG, alcohols and Povidone-Iodine (PI) are the most 
commonly used agents in neonatal units[29-32].
Table 1 summarises the mechanism of action, 
spectrum of activity and disadvantages of individual 
antiseptic agents used in neonates[33,34].
Chlorhexidine: CHG a cationic bisguanide, first 
discovered in the United Kingdom is the most widely 
used antiseptic agent[35]. It is effective against gram-
positive bacteria, somewhat less active against gram 
negative but is effective against resistant organisms 
including Methicillin Resistant Staphylococcus aureus 
(MRSA), Vancomycin resistant enterococcus (VRE), 
Streptococci and Pseudomonas[33,34,36]. CHG has sig-
nificant residual activity and addition of alcohol based 
preparations results in significantly greater residual 
activity than alcohol alone. It also acts in the presence 
of organic material like blood or biofilm[33,34,36]. Its 
antimicrobial activity is slower than that of alcohols. 
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Alcohols: Alcohol can be used alone or in combination 
with other antiseptics, most common being CHG. 
Alcohols have excellent in vitro germicidal activity 
against gram positive and gram-negative bacteria 
including MRSA and VRE, mycobacteria and a 
variety of fungi. They are most effective between 
concentrations of 60%-80% and have a faster onset 
of action but no residual activity. They are not active in 
the presence of organic material.
Iodine: Iodine has been recognised to have antiseptic 
properties since 1800s and has now been replaced 
by iodophors. Iodophors are composed of elemental 
iodine and a polymer carrier of high molecular weight. 
The amount of iodine present determines the level 
of antimicrobial activity[33,37]. Combining iodine with 
polymers increases the solubility, promotes sustained 
release of iodine and reduces the skin irritation[33,37]. 
Most common polymers iodophors used are polyvinyl 
pyrrolidone (povidone) and ethoxylated non-ionic 
detergents (poloxamers).
Hexachlorophene: Hexachlorophene is a bisphenol 
compound with three chlorine molecules. It was widely 
used in hand washing and routine bathing of neonates in 
hospitals. It is bacteriostatic and is the weakest of all the 
antiseptic agents mentioned in the Table 1[33]. It does 
have some residual activity. Hexachlorophene used for 
washing and cord care reduced Staphylococcus aureus 
(S. aureus) colonisation and related omphalitis. However 
in 1970 following cases of vacuolar encephalopathy its 
use has been withdrawn[38]. Following this a number of 
investigations have revealed that incidence of S. aureus 
infections had gone up and some places restarted the 
use of hexachlorophene[39,40]. 
Octenidine: Octenidine is a bis-pyridine compound, 
a cationic substance that binds to the microbial 
envelopes, cell membranes and destroys the cell wall 
of microorganisms by disrupting their metabolism[41]. 
It has a broad spectrum antimicrobial activity against 
gram positive and gram negative bacteria[42,43], 
is effective against resistant organisms including 
MRSA, vancomycin resistant Staphylococcus aureus 
(VRSA)[44], extended spectrum beta-lactamase 
producing bacteriae (ESBL)[45] and pseudomonas[46]. 
It has a low virucidal activity especially against 
hepatitis B virus and herpes simplex viruses but has 
no effect on other viruses, spores or protozoa[41]. Like 
Chlorhexidine it has significant residual activity up to 
24 h[47] and the antiseptic effect is retained even in the 
presence of organic material[44,48]. Octenidine is often 
used in combination with alcohol preparations either 
phenoxyethanol or propanol.
A survey from 90 NICUs in United States on 
CHG use, reported that 61% of the units used CHG 
containing preparations. Twenty-one neonatal units 
used alcohol based CHG preparations[30]. Heron et al[31] 
surveyed the use of antiseptics across 57 neonatal 
units in the United Kingdom in 2013. They reported 
seven different antiseptics were in use and 53% of the 
units used alcohol based CHG preparations in contrast 
to findings of an early survey from 2007 (14% vs 
53%). Majority of the units used alcohol based CHG 
irrespective of GA, birth weight[31]. These surveys 
actually reflect the changes in clinical practice following 
national recommendations to use alcohol based CHG 
antiseptic solutions, the evidence of which is mainly 
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Table 1  Characteristics of topical antiseptic agents used in neonates (World Health Organization 2009)
Antiseptic agent Mechanism of action Advantages Disadvantages Preparations/
compounds
Chlorhexidine Disruption of cytoplasmic 
membranes
Broad spectrum antimicrobial 
activity
Non-sporicidal 0.25%, 0.5%, 1%, 2%, 4% 
- aqueous and alcohol 
basedDenaturation of proteins Kills yeasts Not effective against mycobacteria
Intermediate onset of action Local dermatitis




Alcohols Damages cell membrane Broad spectrum antimicrobial 
activity




Denaturation of proteins Faster onset of action No residual activity
Skin reactions
Systemic absorption
Iodine Forms complexes with proteins 
and lipids
Broad spectrum antimicrobial 
activity
Skin irritation 10% povidone-iodine
Impaired protein synthesis and 
alteration of cell membranes
Sporicidal Systemic absorption with 
hypothyroidism
Effective against mycobacteria
Has some residual activity
Hexachlorophene Inactivates essential enzyme 
systems
Good activity against gram positive, 
weak against gram negative
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mortality. Results of the study showed that sunflower 
oil reduced the mortality by 26% (hazard AR = 0.74; 
CI: 0.55- 0.99, P = 0.04) and aquaphor reduced the 
mortality by 32% (hazard AR = 0.67; CI: 0.57-0.92; 
P = 0.01). This study did not compare neonatal 
sepsis rates. In another large RCT, Edwards et al[53] 
compared the mortality and nosocomial bacterial 
sepsis rates (NBS) following the use of aquaphor 
ointment in preterm infants with birth weight < 1000 
g. This group did not a show a significant reduction in 
combined death or NBS (33.6% vs 30.3%, ARR = 1.07; 
CI: 0.89-1.27; P = 0.22). However, the emollient 
group was noted to have a higher incidence of NBS 
and Coagulase negative Staphylococcus infections 
(18.6% vs 13.3%; ARR = 1.4; CI: 1.08-1.83)[53]. In 
their systematic review, Conner et al[54] reported that 
prophylactic application of topical ointment in preterm 
infants has been associated with significant increase 
of coagulase negative staphylococcal (RR = 1.31; 
95%CI: 1.02-1.70) and other nosocomial infections. 
They concluded that topical ointment should not be 
used routinely in preterm infants. 
A recent systematic review[55] including the studies 
from developing countries, has reported that topical 
emollient therapy significantly reduced neonatal 
mortality by 27% (RR = 0.73; 95%CI: 0.56-0.94) 
and hospital acquired infection by 50% (RR = 0.50; 
95%CI: 0.36-0.71). Topical emollient therapy may be 
a promising intervention to reduce neonatal mortality 
in developing countries but evidence is against this in 
developed countries.
Umbilical cord care: Umbilical cord has been 
recognised as a site of colonisation with bacteria 
especially S. aureus and as a source of infection 
in neonates. Several studies have reported the 
prophylactic use of CHG reduced the colonisation 
rates[55-58]. Verber et al[56] in their prospective study 
on a total of 202 infants, reported that CHG reduced 
the umbilical cord colonisation rates by more than 
half, compared to the control group (16% vs 41%; 
RR = 0.39; CI: 0.24-0.64). In another double blind 
comparative study, Oishi et al[58] compared the effect 
of 80% ethanol in CHG against 80% ethanol alone 
on a total of 100 infants, in reducing umbilical cord 
colonisation by S. aureus. They identified that ethanol 
in CHG was more effective than ethanol alone in 
reducing colonisation with S. aureus (25% vs 58%; P 
< 0.05). However, concerns have been raised that CHG 
delays the separation of cord[57,58]. Three large block 
randomised control trials in developing countries[59-61] 
have shown that use of 4% CHG for umbilical cord 
care has significantly reduced the mortality (RR = 
0.81; 95%CI: 0.71-0.92) and omphalitis (RR = 
0.48; 95%CI: 0.40-0.57) in community settings. 
A recent Cochrane meta-analysis[62] involving 12 
trials all over the world confirmed these benefits in 
developing countries. However there was no strong 
evidence to suggest that this might be beneficial in 
derived from studies on adults and older children. 
ARE THE ANTISEPTICS USED IN 
NEONATES EFFECTIVE?
Antiseptics have been used in neonates for a range 
of different procedures and interventions, in different 
concentrations and combinations. We reviewed the 
current literature based on their purpose of use and 
to identify a preferable effective antiseptic type and 
preparation over other agents.
Antiseptics use to reduce neonatal skin colonisation
Several interventions have been tried to decrease 
the colonisation of newborn skin with pathogenic 
organisms and associated sepsis. There are studies, 
which looked at the use of emollients, antibiotics, 
vaginal CHG washes during labour, umbilical cord 
cleansing and whole body washing to reduce the 
infection rates.
Vaginal CHG washes during labour: A large 
randomized clinical trial (RCT) conducted in South 
Africa, compared 4005 mothers and their 4072 
neonates treated with 0.5% CHG wipes against 4006 
mothers and 4057 neonates in the control group. 
Results from this study showed that CHG wipes did not 
reduce neonatal sepsis (3% vs 4%; CI: 19-24; P = 0.65) 
or GBS colonisation in neonates (54% vs 55%; efficacy 
-0.05%; CI: 9.5-7.9)[49]. Saleem et al[50] conducted a 
placebo controlled RCT on 5008 women in labour and 
their infants, to compare the effect of CHG vaginal 
and infant wipes, on reduction of neonatal sepsis and 
perinatal mortality. CHG vaginal and infant wipes did 
not show a significant reduction in neonatal sepsis and 
mortality (3.1% vs 3.4%; RR = 0.91; CI: 0.67-1.24) 
or composite outcome of neonatal sepsis and perinatal 
mortality (3.8% vs 3.9%; RR = 0.96; CI: 0.73-1.25)[50]. 
Ohlsson et al[51] conducted a systematic review 
to determine whether vaginal CHG during labour 
reduced early onset GBS infections. Authors found that 
Vaginal CHG washes/gel reduced the GBS colonisation 
of neonates, however this was not associated with 
significant reduction in GBS sepsis. Moreover, women 
who received CHG washes developed mild side effects. 
The quality of the included studies varied and was low. 
Therefore authors concluded that use of Vaginal CHG 
is not currently recommended especially in the era of 
intrapartum antibiotic prophylaxis.
Topical ointments: Preterm infants are prone 
for infections as they do not have an effective epi-
dermal skin barrier and topical emollients could 
theoretically provide an effective barrier to prevent 
infections. Darmstadt et al[52] from Bangladesh, in 
their prospective RCT involving a total of 497 preterm 
infants, compared the effect of aquaphor ointment and 
sunflower oil against controls in reducing the neonatal 
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developed countries due to the lack of high quality 
studies involved[62,63] and therefore dry cord care is 
recommended at present.
Regular bathing with CHG on HAI: In adults and 
older children in intensive care, daily bathing with 
CHG washcloths have shown a significant reduction 
in nosocomial infections (4.78 cases vs 6.6 cases per 
1000 patient-days, P = 0.007)[64] and [4.1 cases vs 
10.4 cases of primary blood stream infections (BSIs) 
per 1000 patient-days with CI: 1.2-11.0; P = 0.01][65]. 
Climo et al[64] in addition reported that regular CHG 
bathing reduces the colonisation from multidrug 
resistant organisms (5.1 cases vs 6.6 cases per 1000 
patient-days, P = 0.03). Spencer et al[66] reported a 
similar finding with use of Octenidine in adults from 
a surgical intensive care unit, with 75% reduction in 
MRSA colonisation. 
Large randomised controlled trials from Pakistan 
and South Africa did not show any significant reduction 
in mortality or sepsis in neonates who had prophylactic 
whole body cleansing with CHG wipes[49,50]. Quach et 
al[67] who studied the effect of 2% CHG body wash on 
195 infants with birth weight of 1000 g or more and a 
systematic review on whole body cleansing in neonates 
did not show any beneficial effect on mortality RR = 
0.91, CI: 0.8-1.04, however there was a substantial 
heterogeneity amongst the included studies (I2 = 
80.2%) and therefore evidence is lacking to support 
CHG washes in neonates at present[68].
Recommendations: (1) There is sufficient evidence to 
conclude that application of CHG to umbilical cord can 
prevent omphalitis and neonatal mortality in developing 
countries (Level 1A). More research is needed regar-
ding the concentration of CHG preparation, duration, 
frequency and timing of application. In the absence of 
good evidence to support this in developed countries, 
dry cord care is recommended (Level 2D); and (2) 
Vaginal CHG during labour is not recommended based 
on the available evidence (Level 2B). Topical emollients 
are not routinely recommended for use in preterm 
infants in developed countries (Level 2C), however 
may have an impact in reducing neonatal sepsis and 
mortality in developing countries with high neonatal 
mortality rates (Level 2B). We do not recommend 
regular CHG bathing on the basis of current literature 
evidence (Level 2C). 
Antiseptic use for venepuncture/cannulation/blood 
culture
Venepuncture and intravenous cannulation breach 
the skin integrity increasing the risk of hospital 
acquired infections from invasion of microorganisms 
colonising the skin and intravenous catheter. Blood 
culture contamination is a challenging problem in 
clinical practice with reported contamination rates of 
0.6%-6%; that can lead to unnecessary investigation 
and treatment in otherwise well babies[69,70]. Therefore 
it is important that we use antiseptics that could 
prevent HAI and reduce blood culture contamination 
rates. 
Only a few studies were published in literature on 
use of antiseptics in neonatal population for prevention 
of infections related to venepuncture, blood culture 
sampling or cannulation. Malathi et al[71] compared the 
skin clearance using 0.5% CHG in 70% IPA and 10% 
PI for intravenous cannulation. In the first part skin 
swabs were taken following routine cannulation and in 
the second part swabs were taken after skin cleansing 
with various durations of exposure to either alcoholic 
CHG or PI. Skin cleansing with antiseptics achieved 
a reduction of bacterial colony counts in 90%-99% 
and authors reported no difference between the two 
groups[71]. Lilley et al[72] conducted a prospective 
randomised controlled trial to compare 0.5% CHG and 
0.05% CHG for skin antisepsis prior to intravenous 
cannulation. A total of 85 neonates were randomly 
allocated for exposure to different concentrations of 
CHG and skin surface swabs were taken before and 
after cannulation. Authors found that 0.5% CHG 
produced better bacterial clearance than 0.05% CHG 
(92% vs 38%, P = 0.002)[72]. Another RCT in neonates 
with birth weight of ≥ 1500 g compared the effect 
of 1% aqueous CHG with 10% PI on blood culture 
contamination rates[73]. Use of 1% CHG was associated 
with fewer positive blood culture results in neonates 
> 1500 g. However this study was non-blinded, did 
not control drying times and antiseptics were washed 
off after 30 s. None of the above studies reported 
clinically relevant outcomes such as sepsis rates, other 
morbidity or deaths. 
A Canadian group[74] is currently conducting a 
large RCT comparing the efficacy of 2% CHG in 70% 
IPA against 2% aqueous CHG prior to venepuncture 
that has recently completed recruitment. Around 460 
babies with birth weight of < 1500 g were recruited 
onto the study and bacterial swabs before and up to 
24 h after cleansing were taken for microbiological 
analysis. While we are still awaiting final study results, 
interim results showed identical bacterial clearance 
rates in both groups suggesting that alcoholic com-
ponent is probably not required in very low birth 
weight babies. There is not much evidence available in 
neonates for guidance on appropriate topical antiseptic 
agent prior to venepuncture, blood culture sampling or 
intravenous cannulation. 
Antiseptic use for PICC/CVC/umbilical catheter insertion
Skin commensals are the most common bacteria to 
colonise the central venous catheters[75]. Ponnusamy 
et al[76] showed that colonisation rates of proximal 
catheter segments were higher than catheter tips 
from asymptomatic infants (78% vs 43%, P = 
0.004). Same group in their retrospective study on 
187 peripherally inserted central venous catheter 
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(PICC) removals reported that a positive exit site skin 
swab is associated with an 8 fold increase of catheter 
colonisation (OR = 2.13; CI: 1.18-3.08; P ≤ 0.001), 
and a 14 fold increase of CRBSI (OR = 2.00; CI: 
0.44-4.14, P = 0.01)[77]. 
A multicentre prospective non-randomised clinical 
trial was conducted in two epochs by Garland et al[78] 
to compare the effects of CHG and PI on catheter 
colonisation rates. In a total of 826 catheters in 254 
infants 0.5% CHG significantly reduced the catheter 
colonisation rates (4.7% vs 9.8%, RR = 0.5, CI: 
0.3-0.9; P = 0.01). There were only 2 cases of 
CRBSI and therefore it was not possible to draw any 
conclusions on their effect on clinical outcomes[78]. 
Same group conducted a large multicentre RCT to 
compare the effect of CHG impregnated dressing 
and PI on outcomes of CRBSI, CLABSI and Catheter 
colonisation. Three hundred and thirty-five neonates 
were randomised to CHG impregnated dressing after 
70% alcohol cleansing and 370 to skin disinfection 
with PI. Neonates randomised to the CHG impregnated 
dressing had reduced colonisation rates (15% vs 24%, 
RR = 0.6; CI: 0.5-0.9; P = 0.004). There were no 
differences observed in CRSBI or CLABSI. However, 
significantly more babies < 1000 g (15% vs 0%) 
developed contact dermatitis in the CHG + 70% 
IPA group. These results suggest that CHG + 70% 
IPA is more effective but safety issues need to be 
addressed[79]. 
Andersen et al[37] reported a significant reduction 
in BSIs (21% vs 9%; CI: 0.19-1.0; P = 0.05) with 
2% CHG compared to PI in two cohorts of VLBW 
infants (n = 174) over 12 mo period before and 
after implementing multifactorial prevention stra-
tegies. However there were 4/36 cases of contact 
dermatitis in infants with birth weight less than 
1000 g and therefore studies on weaker solution 
was recommended. During this period they also 
implemented several other interventions including 
changes in hand washing practice, standardisation of 
intravascular device insertion with specialised packs 
and mandatory removal or replacement of peripheral 
IV after 48 h, to reduce nosocomial infections that 
could have contributed to the reduction in BSI. 
Another retrospective study comparing 10% PI and 
0.5% CHG in 70% IPA for PICC insertions in two 
different time periods reported no differences in sepsis 
or CRBSI rates[80]. Jeffries et al[81] in their retrospective 
study compared the short-term outcomes following 
use of CHG or PI prior to PICC insertion. There was 
no observed difference between the two groups in 
mortality or other short-term outcomes in VLBW 
infants. Kieran et al[82] recently completed a large 
RCT comparing the efficacy of 2% CHG in 70% IPA 
with 10% PI to reduce CRBSI in preterm infants. 
Three hundred and ten preterm infants < 31 wk 
gestation were randomised to CHG or PI group for 
PICC/Umbilical catheter insertion. CRBSI rates were 
similar in both groups. However significant differences 
were observed in PI group for hypothyroidism (8% vs 
0%; P = 0.002) and all of them required treatment 
with Thyroxine. No adverse skin reactions were 
reported[82].
Duration of antiseptic application for effective skin 
disinfection
In a retrospective study in preterm neonates com-
paring duration of antiseptic usage with bacterial 
colony counts in skin swabs, Malathi et al[71] have 
reported that 30 s cleansing with 0.5% CHG in 70% 
IPA or 10% PI was more effective than 5 or 10 s 
cleansing in reducing the bacterial colony counts from 
skin swabs.
CHG vs povidone iodine
There is enough evidence in adults to suggest that 
CHG containing solutions are more effective than 
PI for skin preparation for surgery and PICC/CVC 
insertions[26,83]. But in neonates this has not been 
studied in great detail. In vitro studies to compare 
the efficacy of CHG against PI on 33 MRSA isolates 
showed that PI achieved a significantly higher 
logarithmic reduction factor of >5 (tube dilution 
method 4.879 vs 3.004, P < 0.001; microtitre plate 
dilution method 4.5 vs 2.73, P < 0.001), suggesting 
that PI is better than CHG in microbiological studies 
against MRSA strains[84]. In another microbiological 
study from Birmingham, United Kingdom, Adams 
et al[85] compared the efficacy of 2% CHG in 70% 
IPA with 5 different antiseptics (70% IPA, 0.5% 
CHG, 2% CHG, 0.5% CHG in 70% IPA, and 10% PI) 
against S. epidermidis. They found that 2% CHG in 
70% IPA and PI achieved a significant log10 reduction 
factor of > 5 (4.7 vs 2.3-3.6, P = 0.0001) against S. 
epidermidis biofilm compared to other antiseptics but 
there was no statistical difference between CHG and 
PI (4.7 vs 4.4; P = 0.28). Clinical studies in neonates 
involving 0.5% CHG in 70% IPA did not find any 
significant differences between the two antiseptics in 
terms of bacterial clearance rates[71,80]. These studies 
were small and did not include clinical outcomes. A 
large prospective controlled trial compared the two 
antiseptics and found that 0.5% CHG in 70% IPA is 
more effective in reducing the catheter colonisation 
compared to PI in neonates. There were not enough 
infection rates to compare between the two groups[78]. 
A non-blinded RCT showed that 1% CHG achieved 
better blood culture contamination rates compared 
to 10% PI[73]. Jeffries et al[81] reported no differences 
between CHG and PI in mortality or other short-term 
morbidity outcomes in VLBW infants.
In a large RCT on a total of 705 neonates, Garland 
et al[79] compared CHG impregnated dressing followed 
by IPA cleansing against PI in neonates demonstrated 
that CHG significantly reduced catheter colonisation 
(15% vs 24%; RR = 0.6; CI: 0.5-0.9; P = 0.004) 
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but there was no difference in CRBSI. A large RCT 
involving 310 preterm infants comparing 2% CHG in 
70% IPA and PI has completed recruitment recently[82], 
the results are awaited; this might give us further 
insight about a better choice of antiseptics in preterm 
infants. 
Concentration of CHG 0.5% vs 1% vs 2%
There are a handful of studies in neonates that com-
pared the efficacy of different concentration of CHG. 
Adams et al[85] showed that 2% CHG is more effective 
than 0.5% CHG in reducing colony forming units. In a 
prospective RCT 0.5% CHG was found to be superior 
to 0.05% CHG in bacterial clearance as identified from 
skin swabs[72].
Alcoholic vs aqueous CHG preparations
Studies have shown in adults and children that Alcohol 
containing CHG solutions are more effective than 
aqueous solution[86]. However, up to date there are 
no studies to support this in neonates. On the other 
hand, serious concerns have been raised from several 
case reports that alcoholic component is associated 
with severe chemical burns in neonates particularly in 
extreme preterm and VLBW infants (Table 2). In vitro 
studies have shown that alcohol based CHG achieved 
better bactericidal activity than aqueous CHG of the 
same concentration[85]. Shah et al[74] completed a RCT 
comparing the efficacy and safety of aqueous CHG 
against alcoholic CHG in preterm neonates. Preliminary 
results showed similar bacterial clearance, which may 
suggest that aqueous CHG is as effective as alcoholic 
CHG. 
Octenidine
Octenidine, as a topical antiseptic agent has been used 
in some European countries for more than 2 decades 
for prevention of skin, wound and oral cavity infections. 
Efficacy studies involving Octenidine have largely been 
restricted to in vitro microbiological studies or involving 
adult patients; studies on octenidine use in term or 
preterm neonates are scarce.
In vitro study by Junka et al[46] compared the ef-
ficacy of Octenidine, Ethacridine and Povidone Iodine 
against the biofilms of pseudomonas and S. aureus. 
Authors reported that Octenidine was effective in 
eradicating the bacteria from biofilms made by 
pseudomonas in 30 min and was more efficient than 
ethacridine and PI (100% OH vs 66% PI vs 0% 
ethacridine). Similarly Octenidine was as effective as 
PI (100% in 1 min) and more efficient than ethacridine 
(100% vs 60%) in clearing the biofilms by S. aureus. 
In another in vitro study by Amalaradjou et 
al[44] Octenidine hydrochloride was effective not 
only in preventing the biofilm formation but also in 
rapidly inactivating the pre-formed biofilms by S. 
aureus, MRSA, VRSA. Goroncy-Bermes et al[45] have 
showed similar results with Octenidine against ESBL 
producing bacteria in comparison with CHG and poly-
hexamethylen biguanide.
Clinical studies have been noticeably small in num-
bers evaluating Octenidine as an antiseptic agent in 
comparison with other agents such as CHG. Octenidine 
has been shown to be effective in preventing MRSA 
colonisation as well as in eradicating MRSA when used 
as whole body wash[87]. Spencer et al[66] in their 2 
year retrospective uncontrolled study on daily bathing 
with Octenidine for adults in intensive care unit 
reported a significant reduction in MRSA acquisition 
from 25 to 6 (Mean reduction 76%, CI: 42%-90%, 
P < 0.01) and an associated reduction in MRSA 
bacteremia from 3 to 0. A recent study from Lithuania 
evaluating Octenidine’s effect on MRSA decolonisation 
showed that Octenidine was completely effective in 
decontaminating 67% of adult patients and was very 
well tolerated[88]. In a recent cluster cross over study 
on 10936 patients who received either soap and water 
or Octenidine body wash for 6 mo period found that 
there was no significant difference between the two 
groups in MRSA colonisation (3% vs 3.3%; OR = 0.89; 
CI: 0.72-1.11; P = 0.31)[89]. There were no studies 
that compared Octenidine with other antiseptic agent 
in RCTs. 
A pilot study by Dettenkofer et al[90] in 2002 showed 
that Octenidine was more effective than ethanol in 
reducing the CVC insertion site colonisation rates. 
Tietz et al[91] also reported similar observations in 
an uncontrolled observational study in immunocom-
promised patients. Dettenkofer et al[92] in their RCT 
compared the efficacy of Octenidine against 74% 
ethanol when used as a skin antiseptic agent for CVC/
PICC insertion in 400 adult patients. Authors reported 
that Octenidine combination with 30% propanol and 
45% propanol was superior to 74% ethanol with 10% 
propanol combination in reducing the skin colonisation 
rates around CVC (OR = 0.21; CI: 0.11-0.39; P < 
0.0001), catheter tip colonisation rates (7.9% vs 
17.8%; OR = 0.39; CI: 0.2-0.8; P = 0.009) and 
catheter related bloodstream infections (OR = 0.44; CI: 
0.18-1.18; P = 0.08)[90]. Bilir et al[93] in their non-blinded 
randomised trial on 57 patients reported that CHG was 
more effective than Octenidine or Povidone Iodine in 
reducing CVC insertion site colonisation rates, catheter 
hub colonisation and CRBSI rates. 
These studies have been conducted in adult po-
pulation and there has been a noticeable lack of 
studies involving Octenidine use in term and preterm 
neonates.
RECOMMENDATIONS
Based on current evidence
It is possible to conclude CHG may be a better option 
compared to PI given that PI is associated with 
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significant systemic absorption and hypothyroidism. 
However safety issues of CHG preparations still remain 
a concern. Results from a recently completed RCT[82] 
may give us a definitive answer.
Aqueous or alcohol based CHG is as effective - 
results of the on-going trial would hopefully give us 
some answers.
It is not possible to recommend a one particular 
concentration of CHG is better than the others in 
preterm infants because of its mutually conflicting 
efficacy and safety profile.
Are the antiseptics used in clinical practice safe in 
neonates?
Topical antiseptic agents used in adults and older 
children have been considered safe with no significant 
adverse effects noted. Studies have reported that 
Chlorhexidine has been well tolerated and is safe in 
term neonates following exposure for vaginal washing, 
umbilical cord care and whole body cleansing[57,94]. 
However, safety profile of antiseptics has not been 
extensively studied in preterm neonates. Skin of a 
preterm infant is immature, lacks an effective barrier 
Table 2  Studies reporting adverse effects of chlorhexidine use in neonates 
Ref. Design/type Patient 
characteristics (n )




Adverse reaction Systemic effects Comments
Garland et al[78] Prospective 
study
Neonates (n = 111) 0.5% CHG in 70% 
IPA 
PICC insertion None reported Not reported GA not reported
Garland et al[79] RCT Neonates 
(n = 335, including 
98 babies < 1000 g)
0.5% CHG and 
70% IPA, CHG 
impregnated dressing 
after cleansing 
PICC insertion 19 cases of contact 
dermatitis of 
which 15 are < 
1000 g
Not reported Occlusive dressing 
could be the 
cause of contact 
dermatitis
Bührer et al[102] Prospective 
study
Preterm < 27 wk 
GA (n = 24)
2% phenoxyethanol 
and 0.1% octenidine
Skin care Transient 




no adverse effects 
reported
Pezzati et al[57] RCT Preterm < 34 wk 
(n = 101)










VLBW < 1500 g 
(n = 36)
2% aqueous CHG PICC, cannula 
insertion 
Skin erythema and 
burn





Pilot study Neonates (n = 40; 
14 of which < 30 
wk )
2% CHG in 70% IPA PICC insertion Erythema and 
dryness
Not reported Could be from 
dressing
Schick et al[98] Case report Preterm < 28 wk 
GA (n = 2)
IPA Umbilical 
catheterisation





Case report Preterm 27 wk GA 
(n = 1)
Methylated spirit 






Very high ethanol 
and methanol 
levels in blood





Watkins et al[99] Case report Extreme LBW 
babies (n = 2)
Iso propyle alcohol Umbilical 
catheterisation
Skin burns Not reported Care must be taken 
in selection of such 
solutions
Brayer et al[100] Case report Preterm at 35 wk 
(n = 1)
Isopropyl alcohol Umbilical 
catheterisation
Severe skin burn Not reported
Reynolds 
et al[96] 
Case report Preterm infants 24 
wk (n = 2)







Not reported Avoid pooling 
of the antiseptic 
solution and use 
Saline for cleaning 
to wash antiseptic
Mannan et al[101] Case report Preterm 26 wk GA 
(n = 1)







Not reported Alcohol containing 
preparations 
should be avoided 
in NICUs
Bringué 
Espuny et al[97] 
Case report Preterm 26 wk 
(n = 2)




Skin burns Not reported Use of alcoholic 
preparations 




Case report Preterm 25 wk GA 
(n = 1)
2% aqueous CHG Umbilical 
catheterisation 





CHG: Chlorhexidine; GA: General availability; NICU: Neonatal intensive care unit; IPA: Iso propyle alcohol; PICC: Peripherally inserted central venous 
catheter; VLBW: Very low birth weight infants; RCT: Randomized controlled trial.
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and is vulnerable to local damage and systemic absor-
ption of toxic chemicals.
Local adverse reactions: Local adverse reactions 
have been reported with almost all the topical dis-
infectants used in neonatal population. Skin irritation 
in form of erythema and contact dermatitis is the 
most commonly reported adverse event after a topical 
antiseptic use. A national survey in the United States 
reported that 51% (28 of 55) of NICUs using CHG 
noted adverse reactions involving the skin and none of 
them reported systemic side effects[30]. Chemical burns 
were reported by 61% (17 of 28) of NICUs using CHG 
and 13 of the 17 centres (76%) reported that burns 
occurred in neonates with birth weight < 1500 g. In 
another survey from the United Kingdom[31] 30 of 57 
(53%) neonatal units used alcohol based antiseptic 
agents and 7 of 57 (12%) NICUs reported skin burns. 
In Table 2 we have summarised the studies 
that evaluated side effects of aqueous and alcoholic 
antiseptic preparations in neonates. An RCT, few 
prospective studies and several case reports have 
reported chemical skin burns in extreme premature 
babies secondary to use of methylated spirit[95], 
methanol[96,97], IPA[98-101] and 2-phenoxyethanol with 
0.1% Octenidine[102]. In all of these case reports skin 
damage was attributed to the alcohol component of 
the antiseptic. However, a prospective study on VLBW 
infants reported local reactions to aqueous based 2% 
CHG preparation[37]. Similarly another case report 
of an extensive chemical burn related to the use of 
2% aqueous CHG in an extreme preterm infant was 
reported and attributed this to excessive application 
and prolonged skin exposure to CHG[103].
Systemic absorption: Studies have reported that 
CHG can be absorbed in term neonates comparable 
to those in adults and not have any significant side 
effects[104]. Few studies have reported systemic 
absorption of CHG in preterm infants. Milstone et 
al[105] demonstrated that Chlorhexidine inhibits L1 
cell adhesion molecule mediated neurite growth 
of cerebellar granule neurons. This along with 
hexachlorophene’s vacuolar encephalopathy raised 
concerns regarding neurotoxicity. In the reported 
studies, although CHG is detected in their bloods, 
none of them have reported any side effects including 
neurotoxicity or skin toxicity[106-108]. However the 
sample population in these studies did not include 
extreme preterm infants and only very few babies had 
their levels checked during the first 2 wk when skin 
is most immature. Safety of systemic absorption in 
preterm infants has not been studied in great detail 
and significance of raised CHG concentrations is yet to 
be determined in clinical studies.
Further research should focus on differences in CHG 
absorption between aqueous and alcohol based CHG 
preparations, to identify the strength of solution that 
is safe and effective to be used on preterm infants, 
on potential toxicity of absorbed CHG to identify a 
threshold at which this could occur.
Alcohol based preparations: Studies on systemic 
absorption of alcohol in neonates following topical 
antisepsis are very limited. Harpin et al[95] in 1982 
reported very high levels of methanol and ethanol in a 
27 wk gestation baby following use of methylated spirit 
on skin for antisepsis. 
Iodine containing preparations: Preterm infants 
are vulnerable to iodine exposure than term infants 
because of increased skin permeability, immaturity 
of thyroid gland and Wolff-Chaikof effect, and redu-
ced renal clearance. Smerdely et al[109] reported 50 
times higher urinary iodine levels, raised thyrotropin 
levels above 36micromoles/L and significantly lower 
thyroxine levels in 25% of infants iodine exposed (n = 
36) preterm infants compared to CHG exposed (n = 
27) infants. In a cohort study comparing 73 preterm 
infants exposed to iodine containing antiseptics against 
55 exposed to CHG antiseptics, mean thyrotropin 
levels were significantly higher in iodine group (15.4 
mIU/L vs 7.8 mIU/L, P < 0.01)[80]. Khashu et al[110] 
reported hypothyroidism in an extreme preterm 
infant following repeated and prolonged use of topical 
povidone iodine for wound cleaning. This required 
treatment with thyroxine and took 8 wk to resolve. 
There are a few other studies and several case reports 
of hypothyroidism following use of Iodine containing 
topical antiseptics in neonates especially preterm 
infants. Aitken et al[111] in their systematic review 
reported that there is evidence of thyroid dysfunction 
in preterm infants exposed to iodinated antiseptics 
with an incidence ranging from 12-33 per 100 infants. 
However, none of the studies reported long term 
neurodevelopmental outcomes. Authors concluded that 
it was not possible to establish relationship between 
exposure of iodine and occurrence of hypothyroidism 
due to the quality of studies included. They concluded 
that use of iodine containing solutions should be 
restricted in preterms with CHG being an alternative. 
Octenidine containing preparations: Octenidine 
when used in adults for body wash was well tolerated 
and did not cause any adverse effects[87]. Bührer et 
al[102] in their prospective study reported the use of 
Octenidine in extreme preterm infants born before 
27 wk gestation for routine skin antisepsis during 
the first week. They found that Octenidine was well 
tolerated with only one infant developing a transient 
erythematous rash. However, phenoxyethanol was 
absorbed into the systemic circulation but readily 
excreted in urine. Although there were no systemic 
side effects noted authors suggested using Octenidine 
without phenoxyethanol combination in neonates.
Wagner et al[112] in their in vitro study on impact of 
antiseptic agents on radical metabolism, antioxidant 
stress and genotoxic stress in human blood cells 
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compared Octenidine with PI. They reported that 
PI reduced superoxide dismutase (SOD) activity by 
40%, Glutathione peroxidase activity (62%) and 
alpha tocopherol more than Octenidine. There were 
no differences observed in Total antioxidative capacity 
or malondialdehyde in ghosts. Authors concluded 
that exposure of healthy blood cells to Octenidine 
concentrations up to 0.05% for 30 min were safe 
compared to PI.
Recommendations
CHG and Alcohol preparations have been associated 
with severe local reactions, whereas Iodophors are 
associated with increased risk of systemic absorption 
and potential toxicity. Large studies are urgently needed 
to establish the safety of topical antiseptics used in 
neonates especially in preterm infants with focus 
on following: (1) differentiate Aqueous or alcoholic 
component of CHG as the reason for skin irritation in 
preterm neonates; (2) ideal CHG concentration that 
can be safely used in preterm neonates; (3) CHG 
concentrations in blood and their effect on long-term 
neurodevelopment outcomes; (4) isopropyl alcohol 
absorption studies and effect on short term and long 
term outcomes; and (5) systemic absorption of topical 
iodine containing solutions and their effects on thyroid 
function and long-term neurodevelopmental outcomes.
In the meantime we recommend the following on 
the basis of current evidence: (1) Extreme caution is 
recommended for use of topical antiseptics particularly 
alcohol based preparations in extreme preterm infants 
(Level 2D); (2) Care must be taken to avoid pooling 
of the solution under infant and washing with normal 
saline after cleansing with topical antiseptic may 
prevent severe chemical burn in extreme premature 
babies (Level 2D); and (3) Povidone Iodine for skin 
antisepsis should be avoided in extreme preterm 
infants (Level 2C).
CONCLUSION
Skin disinfection with an effective topical antiseptic 
agent could be useful in prevention of HAI. Although 
many antiseptics have been used in neonates for 
several decades, there is no clear guidance regarding 
the best antiseptic for use in neonatal intensive 
care unit. Current evidence based on their efficacy 
and safety studies, does not support the use of 
one antiseptic agent over another. Two large RCTs 
have completed recruitment, but few more large 
multicentre trials are warranted to determine the most 
effective antiseptic preparation, concentration and 
combination for use in neonatal skin disinfection. Large 
trials are also needed to study the adverse effects of 
different antiseptics, effects of systemic absorption 
on developing organ systems in preterm infants with 
a particular focus on long term neurodevelopmental 
outcomes.
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